Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 12HER2-positive Breast Cancer 6Carcinoma, Non-Small-Cell Lung 2Triple Negative Breast Neoplasms 1Salivary Gland Neoplasms 1Rare Tumor 1Lung Neoplasms 1Locally Advanced Breast Cancer 1HER2-positive Metastatic Breast Cancer 1HER2-positive Early Breast Cancer 1HER2-positive Advanced Breast Cancer 1HER2-expressing Advanced Solid Tumors 1HER2 Positive Breast Cancer 1HER2 Insertion Mutation Positive Advanced NSCLC 1Esophageal Squamous Cell Carcinoma 1Breast Neoplasm Female 1Breast Cancer Metastatic 1Breast Cancer Invasive 1Breast Cancer Female 1Advanced Breast Cancer 1

Interventions

pyrotinib 1Tumor Burden 1Trastuzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Breast Cancer Female × pyrotinib × Clear all
NCT06035679 2025-03-12

Pyrotinib Combined With Trastuzumab and Chemotherapy Neoadjuvant Therapy for HER2-positive Breast Cancer

First Affiliated Hospital of Fujian Medical University

Phase NA Recruiting
30 enrolled
Breast

Breast Cancer Female

Data powered by HemOnc (CC BY 4.0) Colophon âš¡